Shelby Newsad
Shelby is an investor at Compound with a focus on Biology and Healthcare. Shelby is an undergraduate in Biochemistry with an engineering minor, an MPhil in Bioscience Enterprise and a PhD in Plant Sciences from University of Cambridge (currently awaiting her oral defense). Her research experience spans neuroscience (Serpe Lab, National Institutes of Health, Bethesda, Maryland), drug discovery (Titz Lab, Helmholtz Institute, Saarbrücken, Germany) and her recent PhD project in microalgae symbioses in the Plant Sciences Department (Smith Lab, University of Cambridge, UK). Through her interest in science translation, she has interned with Merck KGaA at the Innovation Center in Germany and worked with European VC funds, such as Hummingbird Ventures, Ahren Innovation Capital, and Start Codon.
Compound.vc
Bio/acc and Biohack: The Science Behind the Hype
-
Bio/acc and Biohacking have both become popular movements on Twitter of late. This session brings together people who 'hype' them up and people who temper these sectors with science and point out flawed approaches. Get ready for a spicy conversation.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495